On 11 February 2017
GlaxoSmithKline Pharma announced that a meeting of the Board of Directors of the Company will be held on 11 February 2017, inter alia, to consider and approve Un-Audited Financial Results for the quarter and nine months ended 31 December 2016 (Q3).Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
